Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Sweden
  4. NORDIC GROWTH MARKET
  5. Dancann Pharma A/S
  6. News
  7. Summary
    DANCAN   DK0061410487

DANCANN PHARMA A/S

(DANCAN)
  Report
End-of-day quote NORDIC GROWTH MARKET  -  2023-01-25
0.5780 DKK   +0.35%
01/04DanCann Pharma Hires New CFO
MT
01/04DanCann Pharma A/S has appointed Peter Søndergaard as new fulltime CFO
AQ
01/04DanCann Pharma A/S Appoints Peter Søndergaard as CFO
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

BioStock:áDanCann Pharma rides the cannabis legalisation wave

11/04/2022 | 03:22am EST

We are seeing a shift in the political will to decriminalise cannabis, not least in the US and Germany, where significant steps in legislature are being considered. This will also have important effects on the field of medical cannabis, which has already seen a tectonic shift towards a more general acceptance in recent years. Danish biopharma company DanCann Pharma, with one of the world's most modern facilities for manufacturing medical cannabis, is one of the top European players in this field. To inch closer to profitability, the company is now carrying out a rights issue of 28.5 million DKK that ends on November 11th.

Read the article at biostock.se:

https://www.biostock.se/2022/11/dancann-pharma-rides-the-cannabis-legalisation-wave/

This is a press release from BioStock - Connecting Innovation & Capitalhttps://www.biostock.se/en/

https://news.cision.com/dancann-pharma/r/biostock-dancann-pharma-rides-the-cannabis-legalisation-wave,c3661464

(c) 2022 Cision. All rights reserved., source Press Releases - English

All news about DANCANN PHARMA A/S
01/04DanCann Pharma Hires New CFO
MT
01/04DanCann Pharma A/S has appointed Peter Søndergaard as new fulltime CFO
AQ
01/04DanCann Pharma A/S Appoints Peter Søndergaard as CFO
CI
2022DanCann Pharma A/S strengthening the organization with new Head of Regulatory Affairs
AQ
2022Dancann Pharma A/s : A strengthened market position after an impressive H2-2022
AQ
2022Dancann Pharma Unit Receives Regulatory Approval for New Facility in Denmark
MT
2022Dancann Pharma A/s : CannGros ApS' new facilities in Ansager have been approved by the Dan..
AQ
2022Hc Andersen Capital Event 13/12 : Meet the top management in Bawat, Agillic, MapsPeople, C..
AQ
2022Dancann Pharma A/s : The US will enable more research into medical cannabis
AQ
2022DanCann Pharma Falls 20% In Germany amid US Debut
MT
More news
Financials
Sales 2022 6,00 M 0,88 M 0,88 M
Net income 2022 -18,0 M -2,63 M -2,63 M
Net Debt 2022 - - -
P/E ratio 2022 -1,70x
Yield 2022 -
Capitalization 37,6 M 5,49 M 5,49 M
Capi. / Sales 2022 6,26x
Capi. / Sales 2023 2,89x
Nbr of Employees 10
Free-Float 63,1%
Chart DANCANN PHARMA A/S
Duration : Period :
Dancann Pharma A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 0,58
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Jeppe Krog Rasmussen Chief Executive Officer & Director
Peter S°ndergaard Chief Financial Officer
Carsten Trads Chairman
Sarah Mai Lykke-Kjeldsen Chief Operating Officer
Christian Carlsen Vice Chairman
Sector and Competitors
1st jan.Capi. (M$)
DANCANN PHARMA A/S1.40%5
VERTEX PHARMACEUTICALS9.18%82 403
REGENERON PHARMACEUTICALS, INC.2.73%79 279
WUXI APPTEC CO., LTD.20.37%42 325
BIONTECH SE-5.11%34 640
BEIGENE, LTD.18.96%27 198